Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Research Article

Comparative Study of Different Derivative Spectrophotometric Techniques for the Analysis and Separation of Metformin, Empagliflozin, and Glimepiride

Author(s): Khanda F.M. Amin*, Nabil A. Fakhre and Ahmed M. Abdullah

Volume 16, Issue 7, 2020

Page: [916 - 934] Pages: 19

DOI: 10.2174/1573412915666190416122337

Price: $65

Abstract

Background: In some cases, lifestyle changes are not enough to keep type 2 diabetes under control, so there are several medications that may help. Metformin can lower your blood sugar levels, Glimepiride makes more insulin, whereas Empagliflozin prevents the kidneys from reabsorbing sugar into the blood and sending it out in the urine.

Methods: Mean centering, double divisor, ratio spectra-zero crossing, and successive derivative were applied for the estimation of metformin, empagliflozin, and glimepiride respectively, in their prepared laboratory mixtures and in pharmaceutical tablets, without prior chemical separation. The absorption spectra of the mentioned drugs were recorded in the range of 200-400nm.

Results: These methods were linear over concentration ranges of 1.0-10, 2.5-30, and 1.0-10 μgmL-1 of metformin, empagliflozin, and glimepiride respectively. Mean centering for metformin was measured at 234 and 248 nm, while empagliflozin and glimepiride had amplitude values at 276 and 262 nm, respectively. The derivative of double divisor was measured at 234, 278, and 288 nm for metformin, empagliflozin and glimepiride, respectively. The ratio of spectra-zero crossing was quantified at amplitude values of the analytical signal at 234 and 274 nm for metformin and empagliflozin, respectively, whereas glimepiride was determined at 242 and 286 nm. The successive ratio of metformin, empagliflozin, and glimepiride was determined at 284, 242, and 266 nm, respectively.

Conclusion: The methods are validated according to the ICH guidelines where accuracy, precision and repeatability are found to be within the acceptable limit. The methods were studied and optimized. Upon validation linearity, precision, accuracy, LOD, LOQ and selectivity were proved to be operative for the analysis of specified drugs in pharmaceutical dosage configuration. Statistical illustration was done between the suggested methods with the reported methods with consideration to accuracy and precision. No significant difference was found by student’s t-test, F-test and one-way ANOVA.

Keywords: Drug combination, hypoglycemic agents, pharmaceutical preparation, derivative spectrophotometric, zero-crossing, mean centering.

Graphical Abstract
[1]
Forbes, J.M.; Cooper, M.E. Mechanisms of diabetic complications. Physiol. Rev., 2013, 93(1), 137-188.
[http://dx.doi.org/10.1152/physrev.00045.2011] [PMID: 23303908]
[2]
Cheung, B.M.; Ong, K.L.; Cherny, S.S.; Sham, P.C.; Tso, A.W.; Lam, K.S. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am. J. Med., 2009, 122(5), 443-453.
[http://dx.doi.org/10.1016/j.amjmed.2008.09.047] [PMID: 19375554]
[3]
Andrade, E.F.; de Oliveira Silva, V.; Orlando, D.R.; Pereira, L.J. Mechanisms involved in glycemic control promoted by exercise in diabetics. Curr. Diabetes Rev., 2019, 15(2), 105-110.
[http://dx.doi.org/10.2174/1573399814666180214144717] [PMID: 29446746]
[4]
Macha, S.; Mattheus, M.; Halabi, A.; Pinnetti, S.; Woerle, H.J.; Broedl, U.C. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes. Metab., 2014, 16(3), 215-222.
[http://dx.doi.org/10.1111/dom.12182] [PMID: 23859488]
[5]
Resnick, H.E.; Foster, G.L.; Bardsley, J.; Ratner, R.E. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care, 2006, 29(3), 531-537.
[http://dx.doi.org/10.2337/diacare.29.03.06.dc05-1254] [PMID: 16505501]
[6]
Scheen, A.J.; Lefebvre, P.J. Oral Antidiabetic Agents., Drugs, 1998, 55, 225-236. [http://dx.doi.org/10.2165/00003495-199855020-00004].
[7]
Tack, C.J.J.; Smits, P. New drugs for diabetes. Neth. J. Med., 1999, 55(5), 209-211.
[http://dx.doi.org/10.1016/S0300-2977(99)00089-3] [PMID: 10593129]
[8]
Klip, A.; Leiter, L.A. Cellular mechanism of action of metformin. Diabetes Care, 1990, 13(6), 696-704.
[http://dx.doi.org/10.2337/diacare.13.6.696] [PMID: 2162756]
[9]
Zhou, T.; Xu, X.; Du, M.; Zhao, T.; Wang, J. A preclinical overview of metformin for the treatment of type 2 diabetes. Biomed. Pharmacother., 2018, 106, 1227-1235.
[http://dx.doi.org/10.1016/j.biopha.2018.07.085] [PMID: 30119191]
[10]
Ridderstråle, M.; Andersen, K.R.; Zeller, C.; Kim, G.; Woerle, H.J.; Broedl, U.C. EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, activecontrolled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol., 2014, 2(9), 691-700.
[http://dx.doi.org/10.1016/S2213-8587(14)70120-2] [PMID: 24948511]
[11]
Sultana, G.; Kapur, P.; Aqil, M.; Alam, M.S.; Pillai, K.K. Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J. Clin. Pharm. Ther., 2010, 35(3), 267-277.
[http://dx.doi.org/10.1111/j.1365-2710.2009.01080.x] [PMID: 20831529]
[12]
Anna Gumieniczek, A.; Berecka, A. Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological samples. Pharmaceutical and biological assays of new oral antidiabetics. Open Chem., 2016, 14, 215-242.
[http://dx.doi.org/10.1515/chem-2016-0023]
[13]
Tahrani, A.A. SGLT-2 inhibitors as second-line therapy in type 2 diabetes. Lancet Diabetes Endocrinol., 2014, 2(9), 678-679.
[http://dx.doi.org/10.1016/S2213-8587(14)70135-4] [PMID: 24948512]
[14]
Han, J.H.; Oh, T.J.; Lee, G.; Maeng, H.J.; Lee, D.H.; Kim, K.M.; Choi, S.H.; Jang, H.C.; Lee, H.S.; Park, K.S.; Kim, Y-B.; Lim, S. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia, 2017, 60(2), 364-376.
[http://dx.doi.org/10.1007/s00125-016-4158-2] [PMID: 27866224]
[15]
Tahrani, A.A.; Barnett, A.H.; Bailey, C.J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol., 2013, 1(2), 140-151.
[http://dx.doi.org/10.1016/S2213-8587(13)70050-0] [PMID: 24622320]]
[16]
Scott, L.J. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs, 2014, 74(15), 1769-1784.
[http://dx.doi.org/10.1007/s40265-014-0298-1] [PMID: 25274537]]
[17]
Samson, S.L.; Garber, A.J. Metformin and other biguanides: pharmacology and therapeutic usage in: international textbook of diabetes mellitus; defronzo, r.a.; ferrannini, e.; zimmet, p.; k, alberti, g m.m., eds.; john wiley & sons, ltd:,20154, p., , 641-642.
[http://dx.doi.org/10.1002/9781118387658.ch43]
[18]
Inzucchi, S.E.; Bergenstal, R.M.; Buse, J.B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A.L.; Tsapas, A.; Wender, R.; Matthews, D.R. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012, 55(6), 1577-1596.
[http://dx.doi.org/10.1007/s00125-012-2534-0] [PMID: 22526604]]
[19]
Inzucchi, S.E.; Bergenstal, R.M.; Buse, J.B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A.L.; Tsapas, A.; Wender, R.; Matthews, D.R. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38(1), 140-149.
[http://dx.doi.org/10.2337/dc14-2441] [PMID: 25538310]
[20]
McGill, J.B. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. Curr. Diabetes Rev., 2012, 8(4), 257-267.
[http://dx.doi.org/10.2174/157339912800840541] [PMID: 22515702]
[21]
Bangalore, S.; Kamalakkannan, G.; Parkar, S.; Messerli, F.H. Fixed-dose combinations improve medication compliance: a metaanalysis. Am. J. Med., 2007, 120(8), 713-719.
[http://dx.doi.org/10.1016/j.amjmed.2006.08.033] [PMID: 17679131]
[22]
Defronzo, R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009, 58(4), 773-795.
[http://dx.doi.org/10.2337/db09-9028] [PMID: 19336687]
[23]
Abdul-Ghani, M.; Defronzo, R.A.; Eldor, R. combination therapyin type 2 diabetes mellitus in international textbook of diabetes mellitus; defronzo, r.a.; ferrannini, e; zimmet, p.; k, alberti, g m.m., eds.; john wiley & sons, ltd, 20154, p., , 668-708.
[http://dx.doi.org/10.1002/9781118387658.ch46]
[24]
Thakor, N.S.; Amrutkar, S.V. A systematic review of Analytical profiles of SGLT2 inhibitors and their combinations for treatment of type 2 Diabetes Mellitus. Curr. Pharm. Anal., 2018, 14, 1-13.
[http://dx.doi.org/10.2174/1573412914666181105125903]
[25]
John, M.; Gopinath, D.; Kalra, S. Triple fixed drug combinations in type 2 diabetes. Indian J. Endocrinol. Metab., 2015, 19(3), 311-313.
[http://dx.doi.org/10.4103/2230-8210.152739] [PMID: 25932383]
[26]
Patil, M.P.; Radoth, D.S.; Chaudheri, D.P. Development and validation of UV derivative spectrophotometric method for the determination of glimepiride, metformin HCl, and Pioglitazone HCl in bulk and marketed formulated. J. Innov. Pharm. Sci., 2012, 1, 58-62.
[27]
Khan, I.U.; Aslam, F.; Ashfaq, M.; Asghar, M.N. Determination of glimepiride in pharmaceutical formulations using HPLC and firstderivative spectrophotometric methods. J. Anal. Chem., 2009, 64, 171-175.
[http://dx.doi.org/10.1134/s1061934809020130]
[28]
Altinöz, S.; Tekeli, D. Analysis of glimepiride by using derivative UV spectrophotometric method. J. Pharm. Biomed. Anal., 2001, 24(3), 507-515.
[http://dx.doi.org/10.1016/S0731-7085(00)00445-3] [PMID: 11199230]
[29]
Lotfy, H.M.; Mohamed, D.; Mowaka, S. A comparative study of smart spectrophotometric methods for simultaneous determination of sitagliptin phosphate and metformin hydrochloride in their binary mixture. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2015, 149, 441-451.
[http://dx.doi.org/10.1016/j.saa.2015.04.076] [PMID: 25978011]
[30]
Sen, D.B.; Kumar Sen, A.K.; Zanwar, A.; Balarman, R.; Seth, A.K. Determination of alogliptin benzoate and metformin hydrochloride in tablet dosage form by simultaneous equation and absorption ratio method. Int. J. Pharm. Pharm. Sci., 2015, 7, 380-383.
[31]
Neela, M.B.; Ashish, K.M.; Indrajeet, S.; Manish, S.B. Derivative spectrophotometric estimation of metformin hydrochloride and rosiglitazone maleate. Asian J. Chem., 2008, 20(1), 236-240.
[32]
Hoang, V.D.; Nhung, N.P.; Aboul-Enein, H.Y. Recent Developments and Applications of Derivative Spectrophotometry in Pharmaceutical Analysis. Curr. Pharm. Anal., 2013, 9, 261-277.
[http://dx.doi.org/10.2174/1573412911309030005]
[33]
Bonfilio, R.; Araújo, M.B.D.; Salgado, H.R.N. Development and validation of an UV-derivative spectrophotometric method for determination of glimepiride in tablets. J. Braz. Chem. Soc., 2011, 22, 292-299.
[http://dx.doi.org/10.1590/S0103-50532011000200015]
[34]
Hegazy, M.A.; El-Ghobashy, M.R.; Yehia, A.M.; Mostafa, A.A. Simultaneous determination of metformin hydrochloride and pioglitazone hydrochloride in binary mixture and in their ternary mixture with pioglitazone acid degradate using spectrophotometric and chemometric methods. Drug Test. Anal., 2009, 1(7), 339-349.
[http://dx.doi.org/10.1002/dta.60] [PMID: 20355212]
[35]
Abdel-Ghany, M.F.; Abdel-Aziz, O.; Ayad, M.F.; Tadros, M.M. Validation of different spectrophotometric methods for determination of vildagliptin and metformin in binary mixture. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2014, 125, 175-182.
[http://dx.doi.org/10.1016/j.saa.2014.01.055] [PMID: 24548810]
[36]
AbuRuz, S.; Millership, J.; McElnay, J. Determination of metformin in plasma using a new ion pair solid phase extraction technique and ion pair liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 798(2), 203-209.
[http://dx.doi.org/10.1016/j.jchromb.2003.09.043] [PMID: 14643498]
[37]
Amal, K.; Nessreen, S.A.; Abdelaleem, E.A.; Amin, M.M. simultaneous determination of metformin and pioglitazone in presence of metformin impurity by different spectrophotometric and TLC – Densitometric methods. SOJ Pharm. Pharm. Sci., 2018, 5(3), 1-8.
[http://dx.doi.org/10.15226/2374-6866/5/3/00183]
[38]
Onal, A. Spectrophotometric and HPLC determinations of antidiabetic drugs, rosiglitazone maleate and metformin hydrochloride, in pure form and in pharmaceutical preparations. Eur. J. Med. Chem., 2009, 44(12), 4998-5005.
[http://dx.doi.org/10.1016/j.ejmech.2009.09.003] [PMID: 19781822]
[39]
Huttunen, K.M.; Rautio, J.; Leppänen, J.; Vepsäläinen, J.; Keski-Rahkonen, P. Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatography. J. Pharm. Biomed. Anal., 2009, 50(3), 469-474.
[http://dx.doi.org/10.1016/j.jpba.2009.04.033] [PMID: 19481899]
[40]
Porwal, K.P.; Talele, G.S. Development of validated HPLC-UV method for simultaneous determination of Metformin, Amlodipin, Glibenclamaide and Atorvastatin in human plasma and application to protein binding studies. Bull.Fac.Pharm., 2017, 55, 129-139.
[http://dx.doi.org/10.1016/j.bfopcu.2016.10.002]
[41]
Chhetri, H.P.; Thapa, P.; Van Schepdael, A. Simple HPLC-UV method for the quantification of metformin in human plasma with one step protein precipitation. Saudi Pharm. J., 2014, 22(5), 483-487.
[http://dx.doi.org/10.1016/j.jsps.2013.12.011] [PMID: 25473337]
[42]
Merey, H.A.; Ramadan, N.K.; Diab, S.S.; Moustafa, A.A. Chromatographic methods for the simultaneous determination of binary mixture of saxagliptin HCl and Metformin HCl. Bull. Fac. Pharm., 2017, 55, 311-317.
[http://dx.doi.org/10.1016/j.bfopcu.2017.04.002]
[43]
Al-Rimawi, F. Development and validation of an analytical method for metformin hydrochloride and its related compound (1-cyanoguanidine) in tablet formulations by HPLC-UV. Talanta, 2009, 79(5), 1368-1371.
[http://dx.doi.org/10.1016/j.talanta.2009.06.004] [PMID: 19635372]
[44]
Peng, Y.; Chang, Q.; Yang, N.; Gu, S.; Zhou, Y.; Yin, L.; Aa, J.; Wang, G.; Sun, J. Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2018, 1081-1082, 109-117.
[http://dx.doi.org/10.1016/j.jchromb.2018.02.007] [PMID: 29518719]
[45]
Aburuz, S.; Millership, J.; McElnay, J. The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 817(2), 277-286.
[http://dx.doi.org/10.1016/j.jchromb.2004.12.018] [PMID: 15686996]
[46]
Mowaka, S.; Hendy, M.S.; Elmazar, M. M. A.H. A concise comparative mini review between hplc-uv and spectrophotometric analysis of gliptins in pharmaceutical formulations. Pharma Chem., 2017, 9, 140-147.
[47]
Sane, R.T.; Menon, S.N.; Inamdar, S.; Mote, M.; Gundi, G. Simultaneous determination of pioglitazone and glimepiride by highperformance liquid chromatography. Chromatographia, 2004, 59, 451-453.
[http://dx.doi.org/10.1365/s10337-004-0209-9]
[48]
Mokhtar, H.I.; Abdel-Salam, R.A.; Haddad, G.M. Development of a fast high performance liquid chromatographic screening system for eight antidiabetic drugs by an improved methodology of in silico robustness simulation. J. Chromatogr. A, 2015, 1399, 32-44.
[http://dx.doi.org/10.1016/j.chroma.2015.04.038] [PMID: 25943830]
[49]
Wanjari, D.B.; Gaikwad, N.J. Reversed phase HPLC method for determination of glimepiride in tablet dosage form. Indian J. Pharm. Sci., 2005, 67, 253-255.
[50]
Kale, D.; Kakde, R. Simultaneous determination of pioglitazone, metformin, and glimepiride in pharmaceutical preparations using HPTLC method. J. Planar Chromatogr. Mod. TLC, 2011, 24, 331-336.
[http://dx.doi.org/10.1556/JPC.24.2011.4.11]
[51]
Ouanês, S.; Kallel, M.; Trabelsi, H.; Safta, F.; Bouzouita, K. Zerocrossing derivative spectrophotometry for the determination of haloperidol in presence of parabens. J. Pharm. Biomed. Anal., 1998, 17(3), 361-364.
[http://dx.doi.org/10.1016/S0731-7085(97)00174-X] [PMID: 9656144]
[52]
Yardımcı, C.; Ozaltın, N.; Gürlek, A. Simultaneous determination of rosiglitazone and metformin in plasma by gradient liquid chromatography with UV detection. Talanta, 2007, 72(4), 1416-1422.
[http://dx.doi.org/10.1016/j.talanta.2007.01.042] [PMID: 19071778]
[53]
Chen, X.; Gu, Q.; Qiu, F.; Zhong, D. Rapid determination of metformin in human plasma by liquid chromatography-tandem mass spectrometry method. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 802(2), 377-381.
[http://dx.doi.org/10.1016/j.jchromb.2003.12.017] [PMID: 15018802]
[54]
Attimarad, M.; Nagaraja, S.H.; Aldhubaib, B.E.; Nair, A.; Venugopala, K.N. Simultaneous determination of metformin and three gliptins in pharmaceutical formulations using rp hplc: application to stability studies on linagliptin tablet formulation. Ind. J. Pharm, Edu. and Res, 2014, 48, 45-53.
[http://dx.doi.org/10.5530/ijper.48.4.7]
[55]
Bhole, R.P.; Tamboli, F.R. Development and validation of stability indicating HPTLC-MS method for estimation of empagliflozin in pharmaceutical dosage form. TACL, 2018, 8, 244-256.
[http://dx.doi.org/10.1080/22297928.2017.1404929]
[56]
Bhole, R.P.; Wankhede, S.B.; Pandey, M. Stability indicating HPTLC method for simultaneous estimation of empagliflozin and linagliptin in pharmaceutical formulation. TACL, 2017, 7, 76-85.
[http://dx.doi.org/10.1080/22297928.2017.1279567]
[57]
Barapatre, S.R.; Ganorkar, A.V.; Gupta, K.R. Quality by design based HPLC assay method development and validation of Linagliptin in tablet dosage form. Ejpmr, 2017, 4, 486-494.
[58]
El-Bagary, R.I.; Elkady, E.F.; Ayoub, B.M. Spectrophotometric methods for the determination of linagliptin in binary mixture with metformin hydrochloride and simultaneous determination of linagliptin and metformin hydrochloride using high performance liquid chromatography. Int. J. Biomed. Sci., 2013, 9(1), 41-47.
[PMID: 23675288]
[59]
Mallikarjuna, R.N.; Gowri, S.D. RP-HPLC Method for simultaneous estimation and stability indicating study of metformin and linagliptin in pure and pharmaceutical dosage forms. Int. J. Pharm. Pharm. Sci., 2015, 7, 191-197.
[60]
AL-Bratty, M.; Alhazmi, H.A.; Javed, S.A. Lalitha, K.G.; Asmari, M.; Wölker, J.; El Deeb, S. Development and validation of LC–MS/MS method for simultaneous determination of metformin and four gliptins in human plasma. Chromatographia, 2017, 80, 891-899.
[http://dx.doi.org/10.1007/s10337-017-3288-0]
[61]
Polagani, S.R.; Pilli, N.R.; Gajula, R.; Gandu, V. Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. J. Pharm. Anal., 2013, 3(1), 9-19.
[http://dx.doi.org/10.1016/j.jpha.2012.09.002] [PMID: 29403791]
[62]
Ayoub, B.M. UPLC Simultaneous determination of empagliflozin, linagliptin and metformin. RSC Advances, 2015, 116, 95703-95709.
[http://dx.doi.org/10.1039/C5RA17231D]
[63]
El-Zaher, A.A.; Elkady, E.F.; Elwy, H.M.; Saleh, M.A.E.M. Simultaneous spectrophotometric determination of glimepiride and pioglitazone in binary mixture and combined dosage form using chemometric-assisted techniques. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2017, 182, 175-182.
[http://dx.doi.org/10.1016/j.saa.2017.03.028] [PMID: 28437738]
[64]
Ayoub, B.M. Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: Applied to recently approved pharmaceutical formulation. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2016, 168, 118-122.
[http://dx.doi.org/10.1016/j.saa.2016.06.010] [PMID: 27288963]
[65]
Afkhami, A.; Bahram, M. Mean centering of ratio spectra as a new spectrophotometric method for the analysis of binary and ternary mixtures. Talanta, 2005, 66(3), 712-720.
[http://dx.doi.org/10.1016/j.talanta.2004.12.004] [PMID: 18970043]
[66]
Ayoub, B.M.; Emam, R.M.; Youssef, M.M.; El-Kattan, M.N.; Sayed, M.A.; Kowider, A.M.; Seha, A.H.; Rabea, E.A.; Yakout, R.M.; Faried, R.H. Mean centering method for determination of empagliflozin and metformin. Marmara Pharm. J., 2017, 21, 669-674.
[http://dx.doi.org/10.12991/marupj.323590]
[67]
Dinc, E.; Onur, F. Application of a new spectrophotometric method for the analysis of a ternary mixture containing metamizol, paracetamol and caffeine in tablets. Anal. Chim. Acta, 1998, 359, 93-106.
[http://dx.doi.org/10.1016/S0003-2670(97)00615-6]
[68]
Dinç, E. The spectrophotometric multicomponent analysis of a ternary mixture of ascorbic acid, acetylsalicylic acid and paracetamol by the double divisor-ratio spectra derivative and ratio spectra-zero crossing methods. Talanta, 1999, 48(5), 1145-1157.
[http://dx.doi.org/10.1016/S0039-9140(98)00337-3] [PMID: 18967559]
[69]
Berzas Nevado, J.J.; Guiberteau Cabanillas, C.; Salinas, F. Spectrophotometric resolution of ternary mixtures of salicylaldehyde, 3-hydroxybenzaldehyde and 4-hydroxybenzaldehyde by the derivative ratio spectrum-zero crossing method. Talanta, 1992, 39(5), 547-553.
[http://dx.doi.org/10.1016/0039-9140(92)80179-H] [PMID: 18965415]
[70]
EL-Fatatry, H.M.; Mabrouk, M.M.; Hammad, S.F; Elsheikh, S.H. Different ratio spectra methods for simultaneous determination of Olmesartan Medoxomil. Hydrochlorothiazide and Amlodiphine Besylate. J. Innov. Pharm. Biol. Sci, 2016, 3, 166-181.
[71]
Afkhami, A.; Bahram, M. Successive ratio-derivative spectra as a new spectrophotometric method for the analysis of ternary mixtures. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2005, 61(5), 869-877.
[http://dx.doi.org/10.1016/j.saa.2004.06.013] [PMID: 15683791]
[72]
ICH. validation of analytical procedures: text and methodology q2(r1 international conference on harmonization, geneva 2005.
[73]
Bhole, R.P.; Tamboli, F.R. Development and validation of stability indicating HPTLC-MS Method for estimation of empagliflozin in pharmaceutical dosage form. Taylor Fr. Anal. Chem. Lett., 2018, 8, 244-256.
[http://dx.doi.org/10.1080/22297928.2017.1404929]
[74]
Kovaríková, P.; Klimes, J.; Dohnal, J.; Tisovská, L. HPLC study of glimepiride under hydrolytic stress conditions. J. Pharm. Biomed. Anal., 2004, 36(1), 205-209.
[http://dx.doi.org/10.1016/j.jpba.2004.05.005] [PMID: 15351067]
[75]
Zarghi, A.; Foroutan, S.M.; Shafaati, A.; Khoddam, A. rapid determination of metformin in human plasma using ion-pair hplc. j. pharm. biomed. anal., 2003, 31(1), 197-200.
[http://dx.doi.org/10.1016/s0731-7085(02)00608-8] [PMID: 12560065]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy